Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

Temozolomide 64Radiotherapy 53Filgrastim 28Carboplatin 24Etoposide 20Irinotecan 17Vincristine 16Cyclophosphamide 16Cisplatin 15Carmustine 14Peripheral Blood Stem Cell Transplantation 13Magnetic Resonance Spectroscopy 12Bevacizumab 12Thiotepa 11Thalidomide 11Chemotherapy, Adjuvant 11Methotrexate 10Paclitaxel 9Granulocyte Colony-Stimulating Factor 9etoposide phosphate 8Surgical Procedures, Operative 8Procarbazine 8Ifosfamide 8sargramostim 7Topotecan 7O(6)-benzylguanine 7Lomustine 7Busulfan 7Radiation 6Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Central Nervous System Neoplasms × Nivolumab × Clear all
NCT07017816 2026-04-29

JACOB

Children's National Research Institute

Phase EARLY_PHASE1 Recruiting
18 enrolled
CNS

Neoplasms, Germ Cell and Embryonal, Pinealoma, Central Nervous System Neoplasms

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

The University of Texas Health Science Center, Houston

Phase 1 Withdrawn
CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT03838042 2024-02-07

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

University Hospital Heidelberg

Phase 1/2 Recruiting
91 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡